I-Mab (NASDAQ:NBP) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of I-Mab (NASDAQ:NBP) in a research note issued to investors on Monday,Benzinga reports. The firm currently has a $9.00 price target on the stock.

A number of other brokerages have also weighed in on NBP. Wall Street Zen raised shares of I-Mab from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Weiss Ratings began coverage on shares of I-Mab in a research note on Thursday, February 5th. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, I-Mab currently has a consensus rating of “Hold” and an average price target of $9.00.

I-Mab Stock Up 2.5%

Shares of NBP stock opened at $2.90 on Monday. The firm has a market capitalization of $334.34 million, a P/E ratio of -8.06 and a beta of 1.60. I-Mab has a 52 week low of $0.60 and a 52 week high of $6.79.

I-Mab (NASDAQ:NBP) last issued its quarterly earnings data on Thursday, December 18th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On I-Mab

An institutional investor recently bought a new position in I-Mab stock. Taikang Asset Management Hong Kong Co Ltd bought a new stake in shares of I-Mab (NASDAQ:NBP) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 128,765 shares of the company’s stock, valued at approximately $512,000. Taikang Asset Management Hong Kong Co Ltd owned about 0.11% of I-Mab as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 38.38% of the company’s stock.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.